UE2343(Xanamem)
98%
- Product Code: 109857
CAS:
1346013-80-6
| Molecular Weight: | 381.454 g./mol | Molecular Formula: | C₁₉H₁₉N₅O₂S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
UE2343, also known as Xanamem, is primarily investigated for its potential therapeutic applications in neurological disorders. It functions as an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is involved in the regulation of cortisol levels in the brain. By reducing cortisol activity, Xanamem is being explored as a treatment for conditions such as Alzheimer's disease, where elevated cortisol levels are associated with cognitive decline. Early clinical trials have focused on its ability to improve memory and cognitive function in patients with mild cognitive impairment or early-stage Alzheimer's. Additionally, its neuroprotective properties are being studied to assess its broader potential in managing stress-related cognitive impairments and other neurodegenerative diseases.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $2,595.52 |
+
-
|
| 0.010 | 10-20 days | $4,539.79 |
+
-
|
UE2343(Xanamem)
UE2343, also known as Xanamem, is primarily investigated for its potential therapeutic applications in neurological disorders. It functions as an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is involved in the regulation of cortisol levels in the brain. By reducing cortisol activity, Xanamem is being explored as a treatment for conditions such as Alzheimer's disease, where elevated cortisol levels are associated with cognitive decline. Early clinical trials have focused on its ability to improve memory and cognitive function in patients with mild cognitive impairment or early-stage Alzheimer's. Additionally, its neuroprotective properties are being studied to assess its broader potential in managing stress-related cognitive impairments and other neurodegenerative diseases.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :